Volume 3, Issue 6, Pages 467-469 (November 2017) Recurrent dermatofibrosarcoma protuberans treated with neoadjuvant imatinib mesylate followed by Mohs micrographic surgery Natalia M. Fontecilla, BA, Nicole W. Kittler, MD, Larisa Geskin, MD, Faramarz H. Samie, MD, PhD, George Niedt, MD, Thomas Imahiyerobo, MD, Gary Schwartz, MD, Matt Ingham, MD, Jesse M. Lewin, MD JAAD Case Reports Volume 3, Issue 6, Pages 467-469 (November 2017) DOI: 10.1016/j.jdcr.2017.06.019 Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions
Fig 1 Recurrent DFSP presenting as a 4.4- × 3.0-cm firm, tender, subcutaneous nodule with no overlying skin changes. JAAD Case Reports 2017 3, 467-469DOI: (10.1016/j.jdcr.2017.06.019) Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions
Fig 2 Recurrent DFSP histopathologic examination on high power showed atypical spindle cell neoplasm with hypercellularity. JAAD Case Reports 2017 3, 467-469DOI: (10.1016/j.jdcr.2017.06.019) Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions
Fig 3 Posttreatment 3.0- × 2.6-cm mass 6 weeks after initiating imatinib therapy. JAAD Case Reports 2017 3, 467-469DOI: (10.1016/j.jdcr.2017.06.019) Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions
Fig 4 Histopathologic examination on high power of frozen sections of the tumor during Mohs surgery which demonstrates a sparsely cellular spindle cell neoplasm infiltrating the dermis and subcutis. JAAD Case Reports 2017 3, 467-469DOI: (10.1016/j.jdcr.2017.06.019) Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions